ACADIA Pharmaceuticals (NASDAQ:ACAD) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.03, Yahoo Finance reports. The firm had revenue of $43.56 million during the quarter, compared to analyst estimates of $45.30 million. ACADIA Pharmaceuticals had a negative net margin of 231.71% and a negative return on equity of 69.46%.
Shares of ACADIA Pharmaceuticals (ACAD) opened at $24.91 on Thursday. The firm has a market cap of $3,090.00, a P/E ratio of -13.77 and a beta of 3.48. ACADIA Pharmaceuticals has a 12-month low of $24.50 and a 12-month high of $41.20.
Several research firms recently commented on ACAD. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, November 8th. BidaskClub upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 17th. ValuEngine lowered shares of ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Finally, Cowen reiterated a “buy” rating and set a $46.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $49.50.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.